您当前所在的位置:首页 > 产品中心 > 产品详细信息
35943-35-2 分子结构
点击图片或这里关闭

(2R,3R,4S,5R)-2-{5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo[6.3.1.0^{4,12}]dodeca-1(11),3,5,8(12),9-pentaen-2-yl}-5-(hydroxymethyl)oxolane-3,4-diol

ChemBase编号:73145
分子式:C13H16N6O4
平均质量:320.30394
单一同位素质量:320.12330302
SMILES和InChIs

SMILES:
[C@H]1([C@@H]([C@H](O[C@H]1n1c2c3c(c1)c(nn(c3ncn2)C)N)CO)O)O
Canonical SMILES:
OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cc2c3c1ncnc3n(nc2N)C
InChI:
InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)/t6-,8-,9-,13-/m1/s1
InChIKey:
HOGVTUZUJGHKPL-HTVVRFAVSA-N

引用这个纪录

CBID:73145 http://www.chembase.cn/molecule-73145.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(2R,3R,4S,5R)-2-{5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo[6.3.1.0^{4,12}]dodeca-1(11),3,5,8(12),9-pentaen-2-yl}-5-(hydroxymethyl)oxolane-3,4-diol
IUPAC传统名
(2R,3R,4S,5R)-2-{5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo[6.3.1.0^{4,12}]dodeca-1(11),3,5,8(12),9-pentaen-2-yl}-5-(hydroxymethyl)oxolane-3,4-diol
别名
Triciribine
CAS号
35943-35-2
PubChem SID
162038065
PubChem CID
65399

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Selleck Chemicals
S1117 external link 加入购物车 请登录
数据来源 数据ID
PubChem 65399 external link

理论计算性质

理论计算性质

JChem
Acid pKa 12.45568  质子受体
质子供体 LogD (pH = 5.5) -4.271866 
LogD (pH = 7.4) -2.4411151  Log P -1.4642601 
摩尔折射率 90.5553 cm3 极化性 30.775778 Å3
极化表面积 144.47 Å2 可自由旋转的化学键
里宾斯基五规则 true 

分子性质

分子性质

安全信息 药理学性质 产品相关信息 生物活性(PubChem)
保存条件
-20°C expand 查看数据来源
作用靶点
Akt expand 查看数据来源
成盐信息
Free base expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals
Selleck Chemicals -  S1117 external link
Biological Activity
Description Triciribine (TCN, API-2) is a DNA synthesis inhibitor and also inhibits Akt and HIV-1 with IC50 of 130 nM and 20 nM, respectively.
Targets Akt HIV-1
IC50 130 nM [1] 20 nM [2]
In Vitro Triciribine exhibits maximum growth inhibition around 1-10 μM and inhibits phosphorylation of Akt, as well as downstream p70S6K, to basal levels at 100μM (IC50 = 130 nM). Triciribine shows particular promise for inhibiting growth in Nf1 and Trp53 mutant astrocytoma cells in a grade-dependent manner. The WHO II K1861-10 line is inhibited, incompletely (69% maximum inhibition), with a GI50 value of 1.7 μM for Triciribine, whereas higher-grade tumor lines (KR158, KR130, and SF295) are inhibited to a greater extent (>80% maximum inhibition) at lower GI50 values (0.4–1.1 mM). Importantly, Triciribine is much less effective at inhibiting primary astrocytes (GI5013.6 mM), suggesting that this inhibitor may show specificity for tumor cells. [1] Triciribine inihibits HIV-1with an IC50 of 20 nM. Greater than 90% inhibition is achieved at 0.1μM and complete inhibition of syncytia formation is achieved at 5μM. Associated cell toxicity in the same cell line for Triciribine is 46 μM, resulting in selectivity indices of 2250. Triciribine markedly inhibits HIV-1-induced p24 core antigen production, reverse transcriptase, and infectious virus production in a dose-dependent manner using HIV-1 acutedly infected CEM-SS, H9, and persistently infected H9III B and U1 cells. [2] Triciribine inhibits Akt phosphorylation at Thr308 and Ser473 and Akt activity in the human prostate cancer cell line PC-3. Triciribine sensitizes PC-3 cells to TRAIL- and anti-CD95-induced apoptosis, whereas the cells remain resistant to DNA damaging chemotherapeutics. [3] Triciribine is highly selective for Akt and does not inhibit the activation of phosphatidylinositol 3_-kinase, phosphoinositide-dependent kinase-1, protein kinase C, serum and glucocorticoid-inducible kinase, protein kinase A, signal transducer and activators of transcription 3, extracellular signal-regulated kinase-1/2, or c-Jun NH2-terminal kinase. [4]
In Vivo 1 mg/kg/day i.p. treated Triciribine inhibits OVCAR3, OVCAR8 and PANC1 tumor growth, which overexpressing Akt, by 90%, 88% and 80% in nude mice, respectively. However, Triciribine has little effect on the growth of OVCAR5 and COLO357 cells. [4]
Clinical Trials Triciribine is now under the Phase I clinical trial for the safety study of human anti-cytomegalovirus monoclonal antibody.
Features
Combination Therapy
Description Triciribine potentiates growth inhibition by trastuzumab over a 20-fold concentration range. Under combined therapy, breast cancer cell growth is inhibited and apoptosis is induced. Many of the tumors actually decreases in size and four of seven mice have no palpable tumors after 5 weeks of treatment. [5]
Protocol
Kinase Assay [1]
Akt Phosphorylation Changes Assay Cells are grown to 80%–90% confluency and stimulated for 5–10 minutes with 1–10 ng/mL of epidermal growth factor or platelet derived growth factor (PDGF)–AA with or without 10–20 mM of U0126 or LY-294002. Protein lysates (5–20 μg) are separated by 12%–15% SDS PAGE and analyzed by Western blot for Akt, phosphorylated Akt (phospho-Ser 473), MAPK, and phosphorylated MAPK (p44/42 phospho-Thr202/Tyr204) antibodies (1:1000).
Assays for reverse transcriptase activity and p24 core antigen production Virus particles are precipitated from cell-free supernatant as follows: 0.3 mL of 4 M NaCl and 3.6 ml of 30% (wt/vol) polyethylene glycol are added to 7.5 mL of particle-containing medium and the suspension is placed on ice for 2 hours. The suspension is centrifuged in a Sorvall RC-3 centrifuge at 2100 rpm at 4 °C for 45 minutes. The precipitate is resuspended in 200 μL of 50% (vol/vol) glycerol/25 mM Tris-HCl, pH 7.5/5 mM dithiothreitol/ 50 mM KCI/0.025% Triton X-100. Virus particles are disrupted by addition of 100 μL of 0.9% Triton X-100/1.5 M KCI (solution 2). DNA polymerase assays are performed at 37 °C for 1 hour with a 10-μL aliquot of the disrupted virus solution in a final volume of 100 μL containing 40 mM Tris-HC1 (pH 7.8), 4 mM dithiothreitol, 45 mM KCl, and 50 μg of template-primer poly(A)-dT12-18 and poly(C).dG12-18 per mL (with 10 mM Mg2+) or 50 μg of poly(dA).dT12-18 per mL (with 0.25 mM Mn2+). The mixture also contains 15 μM of the appropriate labeled deoxyribonucleoside triphosphates, [3H] dTTP (16 Ci/mmol; 1 Ci = 3.7 × 1010 becquerels) or [3 H]dGTP (12 Ci/mmol). The peak activities are also assayed with various Mg2+ and Mn2+ concentrations with each template-primer, and this activity is compared with that of SSV(simian sarcoma virus-associated virus) [SSV(SSAV)] RT and human DNA polymerases α and γ. For assay of p24 core antigen, the HIV-1 antigen MicroELISA system is used.
Cell Assay [2]
Cell Lines CEM-SS cells
Concentrations 0-500 μM
Incubation Time 48 hours
Methods Triciribine is evaluated for cytotoxicity by seeding CEM-SS cells at a density of 1 × 104 cells/well in growth medium, using a 96-well flat-bottom plate. Serial fivefold dilutions of Triciribine are prepared in growth medium and added to the wells as a second overlay. After a 48-hours incubation at 37 °C, the cells are pulse labeled with [3H]dThd (1 μCi per well, specific activity 20 Ci/mmol) for 6 hours and the cells are harvested to measure total DNA synthesis.
Animal Study [4]
Animal Models OVCAR3, OVCAR8, PANC1, OVCAR5 and COLO357 tumor cells are injected s.c. into 80week-old female nude mice.
Formulation Triciribine is dissolved in 20% DMSO.
Doses 1 mg/kg/day
Administration Triciribine is administrated through i.p. injection once a day.
References
[1] Gursel DB, et al, Nero Oncol, 2011, 13(6), 610-621.
[2] Kucera LS, et al, AIDS Res Hum Retroviruses, 1993, 9(4), 307-314.
[3] Dieterle A, et al, Int J Cancer , 2009, 125(4), 932-941.
[4] Yang L, et al, Cancer Res, 2004, 64(13), 4394-4399.
[5] Lu CH, et al, Clin Cancer Res, 2007, 13(19), 5883-5888.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle